These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 16169371)

  • 1. Relation of lower hematocrit to progression from asymptomatic left ventricular dysfunction to symptomatic heart failure (from the Studies of Left Ventricular Dysfunction Prevention trial).
    Das SR; Dries DL; Drazner MH; Yancy CW; Chae CU
    Am J Cardiol; 2005 Sep; 96(6):827-31. PubMed ID: 16169371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial.
    Das SR; Drazner MH; Yancy CW; Stevenson LW; Gersh BJ; Dries DL
    Am Heart J; 2004 Nov; 148(5):883-8. PubMed ID: 15523322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.
    Daubert C; Gold MR; Abraham WT; Ghio S; Hassager C; Goode G; Szili-Török T; Linde C;
    J Am Coll Cardiol; 2009 Nov; 54(20):1837-46. PubMed ID: 19800193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function.
    Amigoni M; Meris A; Thune JJ; Mangalat D; Skali H; Bourgoun M; Warnica JW; Barvik S; Arnold JM; Velazquez EJ; Van de Werf F; Ghali J; McMurray JJ; Køber L; Pfeffer MA; Solomon SD
    Eur Heart J; 2007 Feb; 28(3):326-33. PubMed ID: 17251259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alcohol consumption and prognosis in patients with left ventricular systolic dysfunction after a myocardial infarction.
    Aguilar D; Skali H; Moyé LA; Lewis EF; Gaziano JM; Rutherford JD; Hartley LH; Randall OS; Geltman EM; Lamas GA; Rouleau JL; Pfeffer MA; Solomon SD
    J Am Coll Cardiol; 2004 Jun; 43(11):2015-21. PubMed ID: 15172406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.
    Go AS; Yang J; Ackerson LM; Lepper K; Robbins S; Massie BM; Shlipak MG
    Circulation; 2006 Jun; 113(23):2713-23. PubMed ID: 16754803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project.
    Kosiborod M; Curtis JP; Wang Y; Smith GL; Masoudi FA; Foody JM; Havranek EP; Krumholz HM
    Arch Intern Med; 2005 Oct; 165(19):2237-44. PubMed ID: 16246989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study.
    Lewis EF; Velazquez EJ; Solomon SD; Hellkamp AS; McMurray JJ; Mathias J; Rouleau JL; Maggioni AP; Swedberg K; Kober L; White H; Dalby AJ; Francis GS; Zannad F; Califf RM; Pfeffer MA
    Eur Heart J; 2008 Mar; 29(6):748-56. PubMed ID: 18308687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
    Anand IS; Rector TS; Kuskowski M; Thomas S; Holwerda NJ; Cohn JN
    Circ Heart Fail; 2008 May; 1(1):34-42. PubMed ID: 19808268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction.
    Ishani A; Weinhandl E; Zhao Z; Gilbertson DT; Collins AJ; Yusuf S; Herzog CA
    J Am Coll Cardiol; 2005 Feb; 45(3):391-9. PubMed ID: 15680718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Predictors of heart failure in chronic chagasic cardiomyopathy with asymptomatic left ventricular dysfunction].
    Petti MA; Viotti R; Armenti A; Bertocchi G; Lococo B; Alvarez MG; Vigliano C
    Rev Esp Cardiol; 2008 Feb; 61(2):116-22. PubMed ID: 18364179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major adverse cardiac event predictors in survivors of myocardial infarction with asymptomatic left ventricular dysfunction or chronic heart failure.
    Kuch M; Janiszewski M; Mamcarz A; Cudnoch-Jedrzejewska A; Dłuzniewski M
    Med Sci Monit; 2009 Jun; 15(6):PH40-8. PubMed ID: 19478711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Screening for asymptomatic left ventricular systolic dysfunction in high-risk patients. Preliminary experience with a program based on the use of ECG and natriuretic peptide].
    Tarantini L; Cioffi G; Di Lenarda A; Valle R; Pulignano G; Del Sindaco D; Frigo G; Soravia G; Tessier R; Catania G
    G Ital Cardiol (Rome); 2008 Dec; 9(12):835-43. PubMed ID: 19119693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study.
    Linde C; Gold M; Abraham WT; Daubert JC;
    Am Heart J; 2006 Feb; 151(2):288-94. PubMed ID: 16442890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of heart rate recovery in patients with heart failure or left ventricular systolic dysfunction.
    Lipinski MJ; Vetrovec GW; Gorelik D; Froelicher VF
    J Card Fail; 2005 Oct; 11(8):624-30. PubMed ID: 16230267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of sex to morbidity and mortality in patients with heart failure and reduced or preserved left ventricular ejection fraction.
    Alla F; Al-Hindi AY; Lee CR; Schwartz TA; Patterson JH; Adams KF
    Am Heart J; 2007 Jun; 153(6):1074-80. PubMed ID: 17540212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymptomatic left ventricular dysfunction: an overlooked part of the continuum of heart failure.
    Misra A; Diwan A; Mann DL; Deswal A
    Heart Fail Monit; 2002; 3(2):42-8. PubMed ID: 12634879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic importance of change in QRS duration over time associated with left ventricular dysfunction in patients with congestive heart failure: the DIAMOND study.
    Fosbøl EL; Seibaek M; Brendorp B; Torp-Pedersen C; Køber L;
    J Card Fail; 2008 Dec; 14(10):850-5. PubMed ID: 19041049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of mortality from pump failure and sudden cardiac death in patients with systolic heart failure and left ventricular dyssynchrony: results of the CARE-HF trial.
    Uretsky BF; Thygesen K; Daubert JC; Erdmann E; Freemantle N; Gras D; Kappenberger L; Tavazzi L; Cleland JG
    J Card Fail; 2008 Oct; 14(8):670-5. PubMed ID: 18926439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced ejection fraction, sudden cardiac death, and heart failure death in the mode selection trial (MOST): implications for device selection in elderly patients with sinus node disease.
    Sweeney MO; Hellkamp AS; Ellenbogen KA; Lamas GA
    J Cardiovasc Electrophysiol; 2008 Nov; 19(11):1160-6. PubMed ID: 18554201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.